Frequent DNA methylation of MiR‐129‐2 and its potential clinical implication in hepatocellular carcinoma
-
- Chang‐Yi Lu
- Biomedical Technology and Device Research Labs Industrial Technology Research Institute Hsinchu Taiwan
-
- Kai‐Yuan Lin
- Department of Medical Research Chi Mei Medical Center Tainan Taiwan
-
- Meng‐Tsung Tien
- Biomedical Technology and Device Research Labs Industrial Technology Research Institute Hsinchu Taiwan
-
- Cheng‐Tao Wu
- Biomedical Technology and Device Research Labs Industrial Technology Research Institute Hsinchu Taiwan
-
- Yih‐Huei Uen
- Department of Medical Research Chi Mei Medical Center Tainan Taiwan
-
- Tzu‐Ling Tseng
- Biomedical Technology and Device Research Labs Industrial Technology Research Institute Hsinchu Taiwan
書誌事項
- 公開日
- 2013-04-12
- 権利情報
-
- http://onlinelibrary.wiley.com/termsAndConditions#vor
- DOI
-
- 10.1002/gcc.22059
- 公開者
- Wiley
この論文をさがす
説明
<jats:p>Hepatocellular carcinoma (HCC) is a highly malignant tumor with poor prognosis and high mortality due to a lack of effective medical treatment and apparent early stage symptoms. Understanding molecular mechanism of cancer development is crucial for HCC diagnosis, prognosis, and treatment. Recently, microRNAs have been shown to play an important role in carcinogenesis, being regulated by DNA methylation in several cases. In this study, a whole genome approach was used to identify methylation‐regulated miRNAs in HCC, finally focusing on miR‐129‐2. MiR‐129‐2 methylation and reduced expression were observed in all examined HCC cell lines but not in normal liver cells and tissues. In 39 (93%) of 42 HCC, the methylation levels of miR‐129‐2 were significantly increased in tumor tissues compared with adjacent normal tissues. Furthermore, miR‐129‐2 methylation was detectable in plasma samples from HCC patients, but not in plasma samples from healthy individuals or patients with liver cirrhosis. At a cut‐off value of −2.36 (log2 transformation of methylation level), it was possible to distinguish HCC from healthy and cirrhotic controls with sensitivity and specificity of 88% and 100%, respectively. This study indicates that miR‐129‐2 methylation is highly accurate in distinguishing HCC patients from cirrhosis patients and healthy individuals, implying its potential utility as an early diagnostic marker for HCC. © 2013 Wiley Periodicals, Inc.</jats:p>
収録刊行物
-
- Genes, Chromosomes and Cancer
-
Genes, Chromosomes and Cancer 52 (7), 636-643, 2013-04-12
Wiley
